Literature DB >> 19025759

The Unified Dyskinesia Rating Scale: presentation and clinimetric profile.

Christopher G Goetz1, John G Nutt, Glenn T Stebbins.   

Abstract

We developed and tested a rating scale aimed to capture the essential features of dyskinesia in Parkinson's disease (PD). Although several scales assess selected attributes of PD-dyskinesias, no comprehensive rating tool exists. Available rating scales were evaluated by the investigators and patient focus groups. Modifications were finalized into the Unified Dyskinesia Rating Scale (UDysRS). The UDysRS has four parts: I: Historical Disability (patient perceptions) of On-Dyskinesia impact (maximum 44 points); II: Historical Disability (patient perceptions) of Off-Dystonia impact (maximum 16 points); III: Objective Impairment (dyskinesia severity, anatomical distribution over seven body regions, and type (choreic or dystonic) based on four activities observed or video-recorded (28 points); IV: Objective Disability based on Part III activities (maximum 16 points). For clinimetric testing, 70 PD patients with all severities of dyskinesia were interviewed and videotaped. Twenty movement disorder experts rated the videotapes with the UDysRS. Internal consistency was examined with Cronbach's alpha. Inter- and intra-rater reliability was evaluated with generalized weighted and nonweighted Kappa coefficients, and intraclass correlation coefficients. Both subjective (Sections I and II) and objective (Sections III and IV) demonstrated high internal consistency (alpha: 0.915, 0.971). Interrater reliability for the objective sections was acceptable for all items and likewise for intrarater reliability except for right leg. Reliable factor structures were found for both subjective (six factors) and objective sections (five factors). The UDysRS is a clinimetrically sound rating scale for dyskinesia in PD, demonstrating acceptable levels of internal consistency and inter- and intra-rater reliability. Testing scale responsivity to treatment interventions is planned. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Year:  2008        PMID: 19025759     DOI: 10.1002/mds.22341

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  65 in total

1.  Observing movement disorders: best practice proposal in the use of video recording in clinical practice.

Authors:  Luisa Sambati; Luca Baldelli; Giovanna Calandra Buonaura; Sabina Capellari; Giulia Giannini; Cesa Lorella Maria Scaglione; Massimo Armaroli; Elena Zoni; Pietro Cortelli; Paolo Martinelli
Journal:  Neurol Sci       Date:  2018-11-17       Impact factor: 3.307

2.  Gamma Oscillations in the Hyperkinetic State Detected with Chronic Human Brain Recordings in Parkinson's Disease.

Authors:  Nicole C Swann; Coralie de Hemptinne; Svjetlana Miocinovic; Salman Qasim; Sarah S Wang; Nathan Ziman; Jill L Ostrem; Marta San Luciano; Nicholas B Galifianakis; Philip A Starr
Journal:  J Neurosci       Date:  2016-06-15       Impact factor: 6.167

3.  Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease.

Authors:  Alessandro Stefani; Francesco Marzetti; Mariangela Pierantozzi; Simona Petrucci; Enrica Olivola; Salvatore Galati; Mario Stampanoni Bassi; Paola Imbriani; Enza Maria Valente; Francesco Saverio Pastore
Journal:  Neurol Sci       Date:  2012-03-22       Impact factor: 3.307

4.  IPMDS-Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the MDS-UPDRS and UDysRS.

Authors:  Christopher G Goetz; Glenn T Stebbins; Lu Wang; Nancy R LaPelle; Sheng Luo; Barbara C Tilley
Journal:  Mov Disord Clin Pract       Date:  2014-05-14

5.  Independent Spanish Validation of the Unified Dyskinesia Rating Scale.

Authors:  Esther Cubo; Christopher G Goetz; Glenn T Stebbins; Nancy R LaPelle; Barbara C Tilley; Lu Wang; Sheng Luo
Journal:  Mov Disord Clin Pract       Date:  2014-08-05

6.  GLP-1 receptor agonists for Parkinson's disease.

Authors:  Caroline A Mulvaney; Gonçalo S Duarte; Joel Handley; David Jw Evans; Suresh Menon; Richard Wyse; Hedley Ca Emsley
Journal:  Cochrane Database Syst Rev       Date:  2020-07-23

7.  A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.

Authors:  Ruth B Schneider; Peggy Auinger; Christopher G Tarolli; Julia Iourinets; María Cristina Gil-Díaz; Irene H Richard
Journal:  Parkinsonism Relat Disord       Date:  2020-10-13       Impact factor: 4.891

8.  Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD).

Authors:  Jerrold L Vitek; Kelly E Lyons; Roy Bakay; Alim-Louis Benabid; Guenther Deuschl; Mark Hallett; Roger Kurlan; Joseph J Pancrazio; Ali Rezai; Benjamin L Walter; Anthony E Lang
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

9.  Differential item functioning in the Unified Dyskinesia Rating Scale (UDysRS).

Authors:  Sheng Luo; Yuanyuan Liu; Jeanne A Teresi; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord       Date:  2017-06-01       Impact factor: 10.338

Review 10.  Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease.

Authors:  Christiana Ossig; Angelo Antonini; Carsten Buhmann; Joseph Classen; Ilona Csoti; Björn Falkenburger; Michael Schwarz; Jürgen Winkler; Alexander Storch
Journal:  J Neural Transm (Vienna)       Date:  2015-08-08       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.